Refine by
Ulcerative Colitis Articles & Analysis
23 news found
Tofacitinib Citrate Tofacitinib Citrate is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It works by suppressing the immune system and reducing inflammation in the body. ...
Walid joined the company in early 2017 and led it through a critical and transformative phase, including the successful completion of the Phase 3 studies of filgotinib in rheumatoid arthritis and ulcerative colitis. We recognize his important contribution to building out the development organization and to bringing our company to the fully integrated biotech that ...
“It is comforting to see that we still have the option for a benefit-oriented use of filgotinib in ulcerative colitis to provide fast anti-inflammatory efficacy to the main patient ...
Commercial progress Since becoming European marketing authorization holder (MAH) of Jyseleca®, we successfully set up our own commercial capabilities and are currently operational throughout Europe in the current approved indications RA and ulcerative colitis (UC). The financial results for the third quarter of 2022 show continued strong sales momentum for ...
Q3 2022 operational review and recent events Jyseleca commercial & regulatory progress Strong adoption across Europe with reimbursement for rheumatoid arthritis (RA) in 15 countries and for ulcerative colitis (UC) in 10 countries Marketing Authorization Application (MAA) submitted for the treatment of UC to Swissmedic, the regulatory authority in ...
The Company is also conducting research to inform further development of microbiome therapeutics for ulcerative colitis. For more information, please visit www.serestherapeutics.com. ...
The Company is also conducting research to inform further development of microbiome therapeutics for ulcerative colitis. For more information, please visit www.serestherapeutics.com. ...
Inflammatory bowel disease (IBD), mainly divided into Crohn's disease (CD) and ulcerative colitis (UC), are diseases whose causes are not fully understood and for which there is no cure. ...
Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis and SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections and graft-versus-host disease as well as additional preclinical stage programs targeting Infection ...
The Company is also conducting research to inform further development of microbiome therapeutics for ulcerative colitis. For more information, please visit www.serestherapeutics.com. ...
Building upon SER-109, and in addition to SER-155, Seres is also evaluating additional preclinical stage programs in indications such as cancer neutropenia, solid organ transplant, and antimicrobial resistant infections more broadly. Ulcerative colitis (UC) research:The Company previously reported clinical, microbiome and metabolomic data from the SER-287 Phase ...
The project, to support the ongoing development of Microbiotica’s Live Bacterial Therapeutic (LBT) MB310 for the treatment of ulcerative colitis (UC), was funded following an extensive review process including industrial and clinical key opinion leaders, and is strong recognition of Microbiotica’s unique capabilities in the discovery and development ...
MB310 is a fully defined LBT comprising a consortium of bacteria for the treatment of Ulcerative Colitis (UC) identified as being linked to remission in a UC faecal transplant clinical study. ...
Proceeds from the Series A financing will allow completion of the development of the company’s first product for treating ulcerative colitis, readying it for human trials, and further the development of the overall technology platform. ...
Vedanta plans to move this consortium forward to a Phase 2 study in patients with ulcerative colitis. The study will be partially funded with the proceeds from a $25 million investment from Pfizer, as part of the Pfizer Breakthrough Growth Initiative, which was announced in January 2021. ...
IBD is a lifelong, chronic disease that affects the digestive system, and includes Crohn's disease and ulcerative colitis. Bouts can last for days, weeks or months at a time. ...
Recent achievements include a key new strategic collaboration with Cancer Research UK and Cambridge University Hospitals, progressing lead programmes in ulcerative colitis and immuno-oncology towards the clinic, and moving into purpose-configured facilities at Chesterford Research Park. ...
Eli Lilly and Company (NYSE: LLY) announced today that mirikizumab met the primary and all key secondary endpoints in LUCENT-1, a 12-week Phase 3 induction study evaluating the efficacy and safety of mirikizumab for the treatment of patients with moderate to severe ulcerative colitis (UC). LUCENT-2, a multicenter, randomized, double-blind, placebo-controlled ...
This collaboration is a further validation of the Company’s technology following a major collaboration with Genentech/Roche in Inflammatory Bowel Disease (IBD), and one with University of Adelaide to develop novel bacterial therapy for Ulcerative Colitis (UC). The therapeutic in UC has also made significant progress in the past 12 months, with key ...
This collaboration is a further validation of the Company’s technology following a major collaboration with Genentech/Roche in Inflammatory Bowel Disease (IBD), and one with University of Adelaide to develop novel bacterial therapy for Ulcerative Colitis. The OBN Awards, now in their 12th year, celebrate outstanding achievement throughout the life sciences ...